Glatiramer Acetate in Multiple Sclerosis: A Review
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Multiple sclerosis (MS) is considered to be primarily an inflammatory autoimmune disease. Over the last 5 years, our view of the pathogenesis of MS has evolved considerably. The axonal damage was recognized as an early event in the disease process and as an important determinant of long‐term disability. Therefore, the antiinflammatory and neuroprotective strategies are thought to represent promising approach to the therapy of MS. The therapeutic potential of glatiramer acetate (GA), a synthetic amino acid polymer composed of a mixture of l‐glutamic acid, l‐lysine, l‐alanine, and l‐tyrosine in defined proportions, in MS has been apparent for many years. GA has been shown to be effective in preventing and suppressing experimental allergic encephalomyelitis (EAE), the animal model of MS. GA has been, therefore, evaluated in several clinical studies and found to alter the natural history of relapsing‐remitting (RR)MS by reducing the relapse rate and affecting disability. These findings were confirmed in open‐label follow‐up trials covering more than 10 years of treatment. The trials demonstrated sustained efficacy for GA in slowing the progression of disability. The clinical therapeutic effect of GA is consistent with the results of magnetic resonance imaging (MRI) findings from various clinical centers. At a daily standard dose of 20 mg, s.c., GA was generally well tolerated. The induction of GA‐reactive T‐helper 2‐like regulatory suppressor cells is thought to be the main mechanism of the therapeutic action of this drug. In addition, it was recently shown that GA‐reactive T cells produce neurotrophic factors (e.g., brain‐derived neurotrophic factor [BDNF]) that protect neurons and axons in the area of injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Cited by
An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis
Garg, N., & Smith, T. W. (2015) · Brain and Behavior · doi:10.1002/brb3.362 · Cited by 348
Biodegradable Polymers Derived From Amino Acids
Khan, W., Muthupandian, S., Farah, S., Kumar, N., & Domb, A. J. (2011) · Macromolecular Bioscience · doi:10.1002/mabi.201100324 · Cited by 72
The relevance of BDNF for neuroprotection and neuroplasticity in multiple sclerosis
Maiworm, M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1385042 · Cited by 27
Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
Moreau, T. (2009) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(09)70005-x · Cited by 2
“Indeed, a rapid reduction of relapse rates following initiation of glatiramer acetate treatment compared to placebo has been a consistent finding of clinical studies of this drug in relapsing remitting disease [14].”
Metadata
- Authors
- Ruggieri, M., Avolio, C., Livrea, P., & Trojano, M.
- Venue
- CNS Drug Reviews
- Publisher
- Wiley
- Published
- 2007-06
- Volume
- 13
- Issue
- 2
- Pages
- 178-191
- ISSN
- 1080-563X (ISSN-L)
- 1527-3458
- OpenAlex
- W2044387763
- Cited by
- 64
- References
- 1
- FWCI
- 3.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glatiramer Acetate in Multiple Sclerosis: A Review. https://app.cochat.ai/papers/10.1111/j.1527-3458.2007.00010.x
- The paper
- Ruggieri, M., Avolio, C., Livrea, P., & Trojano, M. (2007). Glatiramer Acetate in Multiple Sclerosis: A Review. CNS Drug Reviews. https://doi.org/10.1111/j.1527-3458.2007.00010.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.